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Abstract
We analyzed a recently reported (K. Seno, T. Okuno, K. Nishi, Y. Murakami, F. Watanabe, T. Matsuur, M. Wada, Y.
Fujii, M. Yamada, T. Ogawa, T. Okada, H. Hashizume, M. Kii, S.-H. Hara, S. Hagishita, S. Nakamoto, J. Med. Chem. 43
(2000)) pyrrolidine-based inhibitor, pyrrolidine-1, against the human group IV cytosolic phospholipase A2 K-isoform
(cPLA2K). Pyrrolidine-1 inhibits cPLA2K by 50% when present at approx. 0.002 mole fraction in the interface in a number of
in vitro assays. It is much less potent on the cPLA2Q isoform, calcium-independent group VI PLA2 and groups IIA, X, and V
secreted PLA2s. Pyrrolidine-1 blocked all of the arachidonic acid released in Ca2 ionophore-stimulated CHO cells stably
transfected with cPLA2K, in zymosan- and okadaic acid-stimulated mouse peritoneal macrophages, and in ATP- and Ca2
ionophore-stimulated MDCK cells. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Phospholipase A2 (PLA2) catalyzes the hydrolysis
of the sn-2 ester of glycerophospholipids to release a
fatty acid and a lysophospholipid. Mammalian
PLA2s comprise a superfamily of enzymes. Nine dif-
ferent secreted PLA2s have been identi¢ed in humans
[1^4]. These small (approx. 16 kDa), disul¢de-rich
enzymes require millimolar calcium for catalytic ac-
tivity, and are secreted by the classical secretory
pathway in response to proin£ammatory cytokines
or by degranulation [5]. Functions of secreted PLA2s
include arachidonate release for eicosanoid produc-
tion [6] and bactericidal activity [7].
An 87 kDa group IV cytosolic phospholipase A2
K-isoform (cPLA2K) uses its C2 domain to translo-
cate to the perinuclear region of cells in response to a
rise in intracellular calcium [8,9]. This enzyme medi-
ates agonist-induced arachidonic acid release in a
0005-2736 / 01 / $ ^ see front matter ß 2001 Elsevier Science B.V. All rights reserved.
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Abbreviations: BEL, (E)-6-(bromomethylene)tetrahydro-3-(1-
naphthalenyl)-2H-pyran-2-one; BSA, bovine serum albumin;
cPLA2K and cPLA2Q, human cytosolic phospholipase A2 K- and
Q-isoforms; DOPM, 1,2-dioleoylphosphatidylmethanol; GLU, es-
ter formed between Q-linolenic acid and umbelliferone; iPLA2L
and iPLA2Q, calcium-independent phospholipases A2 L- and
Q-isoforms; PLA2, phospholipase A2
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variety of mammalian cells [10]. The L- and Q-iso-
forms of cPLA2 have been recently identi¢ed
[11,12], but their physiological functions are un-
known.
A second cytosolic PLA2 has been cloned [13^15]
that does not require Ca2 for catalysis. It is classi-
¢ed as a group VIA PLA2 and is designated iPLA2L
[16,17] to distinguish it from a membrane-associated,
Ca2-independent PLA2 that contains a peroxisomal
targeting sequence and is designated iPLA2Q. These
enzymes contain a GXSXG lipase consensus motif
and are inhibited by the mechanism-based inactiva-
tor (E)-6-(bromomethylene)tetrahydro-3-(1-naphtha-
lenyl)-2H-pyran-2-one (BEL) [18,19].
PLA2 inhibitors that are speci¢c for each of the
superfamily members and are cell permeable are use-
ful tools for understanding the role of these enzymes
in cellular processes. Key issues for the proper anal-
ysis of PLA2 inhibitors have been reviewed elsewhere
[20,21], and a recent review of active site-directed
PLA2 inhibitors has appeared [22]. Cell permeable
and potent inhibitors of cPLA2K include the ana-
logues of arachidonic acid with the COOH group
replaced with COCF3 (AACOCF3 [23]) or PO(O-
Me)F (MAFP [24]). These ¢rst-generation cPLA2K
inhibitors have been extremely useful in probing
the role of this enzyme in cellular processes including
arachidonic acid release in thrombin-stimulated
platelets [24^26]. However, these arachidonic acid
analogues block enzymes in the eicosanoid pathway
that oxygenate arachidonate [26], and they also in-
hibit iPLA2L [27].
Recently a class of pyrrolidine-containing com-
pounds have been reported to act as potent inhibi-
tors of cPLA2K in vitro and to block arachidonate
release in calcium ionophore-stimulated THP-1 cells
[28]. One of the most potent compounds in the series,
designated pyrrolidine-1 in the present study, is
shown in Fig. 1. Here, we report that low- and
sub-micromolar concentrations of pyrrolidine-1
block the action of cPLA2K in a number of di¡erent
in vitro assays and are much less potent on other
PLA2 family members (cPLA2Q, iPLA2L and human
groups IIA, V, and X secreted PLA2s). We also re-
port that low- and sub-micromolar concentrations of
pyrrolidine-1 block arachidonate acid liberation from
membrane phospholipids in a number of di¡erent
mammalian cells stimulated with a diverse array of
agonists.
2. Materials and methods
2.1. Materials
Pyrrolidine-1 was synthesized as described previ-
ously [29]. Its structure was con¢rmed by 1H-NMR
and electrospray mass spectrometry. The compound
was judged to be pure by thin layer chromatography
on a silica plate and by HPLC on a reverse-phase
(C18) column. Other materials were obtained as
follows: GLU [30], BEL (Cayman Chemicals),
phospholipids (Avanti), radiolabeled phospholipids
(NEN), 6His-tagged cPLA2K [31], 6His-tagged
cPLA2Q (submitted for publication), iPLA2L [32], hu-
man groups IIA, X and V secreted PLA2s [33,34] (to
be published).
2.2. In vitro inhibition studies
For all assays, pyrrolidine-1 was added from a
stock solution in DMSO such that the ¢nal concen-
tration of DMSO in the assay did not exceed 1%. The
e¡ect of the pyrrolidine-1 on PLA2 activity of puri¢ed
cPLA2K (40 ng) and cPLA2Q (4 ng) was tested using
30 WM 1-palmitoyl-2-[14C]arachidonylphosphatidyl-
choline co-sonicated with 9 WM dioleoylglycerol. As-
says (50 Wl) were carried out in 50 mM HEPES, pH
7.4, 1 mM EGTA, 150 mM NaCl and either 2 WM
cPLA2Q or 1 WM cPLA2K. Inhibitor was added and
reactions started by the addition of enzyme. After
incubation at 37‡C for 2 min, reactions were stopped
by the addition of Dole’s reagent, and fatty acids
extracted as described previously [35].Fig. 1. Structure of pyrrolidine-1.
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Pyrrolidine-1 was also tested as a cPLA2K inhib-
itor using a 1 ml mixed-micelle assay (50 mM Tris,
pH 8.0, 150 mM NaCl, 0.3 mM CaCl2, 0.2 mM
EGTA, 30% glycerol (v/v), 0.024% Triton X-100
(w/v), 100 WM 1,2-dioleoylphosphatidylmethanol
(DOPM), 2.8 WM GLU)) and a 1 ml vesicle assay
(50 mM Tris, pH 8.0, 0.3 mM CaCl2, 0.2 mM
EGTA, 30% glycerol (v/v), 100 WM DOPM (0.1 Wm
extruded vesicles)) as described [30].
cPLA2Q was also assayed with [3H]arachidonic
acid-labeled Sf9 cells expressing cPLA2Q in which
endogenous membrane phospholipids are used as
substrate. Sf9 cells (6U106 cells per 100 mm dish)
were infected with control or recombinant viruses.
After 30 h, cells were labeled with 0.5 WCi/ml
[3H]arachidonic acid for 18 h in medium containing
10% FBS. Cells were washed twice with PBS contain-
ing 0.01% fatty acid-free bovine serum albumin
(BSA) and then once in ice-cold homogenization
bu¡er (50 mM HEPES, pH 7.4, 100 mM KCl,
5 mM NaCl, 1 mM EGTA, 10 Wg/ml pepstatin A,
16 Wg/ml benzamidine HCl and 10 Wg/ml phenan-
throline). Cells were scraped in homogenization bu¡-
er and sonicated three times (15 s each) on ice. Ly-
sates were centrifuged at 100 000Ug at 4‡C for 1 h.
Membranes were suspended in homogenization bu¡-
er containing 5 mM MgCl2, 1 mg/ml fatty acid-free
BSA and 2 WM CaCl2 and pyrrolidine-1. Samples
were incubated at 37‡C for 10 min. Lipids were ex-
tracted by the Bligh and Dyer method and free fatty
acids separated by on a silica plate TLC (oleic acid
standard) with hexane:ether:acetic acid (80:20:2).
The fatty acid region was scraped and submitted to
scintillation counting.
iPLA2L was incubated for 3 min at room temper-
ature with BEL (added from an ethanol stock solu-
tion) and at 37‡C for 2 min with pyrrolidine-1 in 40
mM Tris, pH 7.3, 5 mM EGTA. Five microliters of
1-palmitoyl-2-(1[14C]linoleoylphosphatidylcholine in
ethanol were added (2.5 WM, 55 Ci/mol). After a
5 min incubation at 37‡C, 100 Wl of butanol was
added. After centrifugation, 25 Wl of the upper layer
was co-spotted with oleic acid on a silica gel G TLC
plate which was developed with petroleum ether:
ether:acetic acid (80:20:1). The fatty acid region
(I2 vapor) was scraped and submitted to scintillation
counting.
Human groups IIA, V, and X were assayed with
30 WM 1-palmitoyl-2-oleoylphosphatidylglycerol
vesicles (0.1 micron [30]) in Hanks’ balanced salt so-
lution with 1 mM CaCl2 and MgCl2 at 37‡C using
the fatty acid binding protein assay [34].
2.3. Studies with cultured mammalian cells
CHO cells stably transfected with wild-type
cPLA2K, radiolabeling with [3H]arachidonic acid,
and A23187-dependent arachidonate release have
been described previously [36]. Cells were preincu-
bated in complete culture medium containing various
concentrations of pyrrolidine-1 for 15 min and with
1 WM PMA for 10 min prior to stimulation with 1 or
10 WM A23187 for 20 min (37‡C).
MDCK cells were plated at 1.2U106 cells per well
in 12-well tissue culture plates in DMEM containing
10% FBS and incubated overnight. Cells were
washed twice with Hanks’ bu¡ered saline solution
and then incubated overnight with 0.25 WCi/well
[3H]arachidonic acid (98 Ci/mmol) in DMEM con-
taining 0.2% BSA.
Mouse peritoneal macrophages were harvested and
plated at 1U106 cells per well in 24-well tissue cul-
ture plates in DMEM containing 10% FBS as pre-
viously described [35,37,38]. Cells were allowed to
attach for 2 h at 37‡C and then washed twice with
Hanks’ balanced salt solution, before being labeled
overnight with 0.2 WCi/well [3H]arachidonic acid in
DMEM containing 10% FBS.
After labeling, MDCK and macrophages were
washed three times with DMEM containing 0.05%
BSA and then preincubated with the indicated inhib-
itor concentrations for 30 min at 37‡C. MDCK cells
were stimulated for 3 min with either 100 nM ATP
or 1 WM ionomycin. Mouse peritoneal macrophages
were stimulated either with zymosan (10 particles per
cell) for 60 min or 1 WM okadaic acid for 90 min.
Radioactivity released into the supernatant was
counted and calculated as the percentage of total
radioactivity (cellular and released). Results are
represented as a percentage of maximum response
and are representative of three individual experi-
ments.
3. Results and discussion
3.1. In vitro PLA2 inhibition studies
Pyrrolidine-1 was tested as an inhibitor of cPLA2K
using a number of di¡erent in vitro assays. Previous
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studies have shown that cPLA2K binds tightly to
anionic DOPM vesicles [30,31] and to zwitterionic
phosphatidylcholine vesicles [31,39,40] and displays
similar speci¢c activity on both [31]. The fatty acid
ester GLU is hydrolyzed by cPLA2K to release um-
belliferone, which is detected in a real-time £uorimet-
ric assay [30]. Fig. 2A shows that pyrrolidine-1 is a
potent inhibitor of cPLA2K-catalyzed hydrolysis of
GLU present in DOPM vesicles, displaying an IC50
in this assay of 0.18 WM (0.0018 mole fraction in the
interface).
As shown in Fig. 2B, the same compound also is a
potent cPLA2K inhibitor, IC50 = 1.8 WM (approx.
0.002 mole fraction in the interface), when analyzed
with a mixed-micelle assay composed of GLU in
Triton X-100 micelles containing DOPM to facilitate
interfacial binding of enzyme [30]. As shown in Fig.
2C, pyrrolidine-1 also displays potent inhibition of
cPLA2K acting on 1-palmitoyl-2-arachidonylphos-
phatidylcholine vesicles containing 23 mole% 1,2-di-
oleoylglycerol (IC50 = 0.07 WM, 0.0017 mole fraction
in the interface). Diglyceride leads to an increase in
cPLA2K activity on phosphatidylcholine vesicles
[41,42].
It is di⁄cult to compare the relative IC50 values
for pyrrolidine-1 obtained with the three di¡erent in
vitro cPLA2K assays. This is because with the di¡er-
ent interface concentrations, the surface concentra-
tion of inhibitor, which determines the degree of in-
hibition, is di¡erent in the di¡erent assays. Also the
surface concentration of substrates and the interfa-
cial Km values are di¡erent in the di¡erent assays.
Finally, each of the diluent amphiphiles, DOPM,
Triton X-100, 1,2-dioleoylglycerol, competes to dif-
ferent extents with pyrrolidine-1 for the binding to
cPLA2K. However, it is clear that pyrrolidine-1 is a
potent cPLA2K inhibitor since it inhibits when
Fig. 2. Inhibition of cPLA2K by pyrrolidine-1 measured with
the DOPM/GLU vesicle assay (A) and the Triton X-100/
DOPM/GLU mixed-micelle assay (B). C shows the inhibition
of cPLA2K (b) and cPLA2Q (a) measured with the 1-palmitoyl-
2-arachidonylphosphatidylcholine/1,2-dioleoylglycerol vesicle as-
say. Error bars are the standard deviations determined from 2^
3 independent assays. Other conditions are given in Section 2.
Solid lines in A and B are the theoretical inhibition curves for
competitive inhibition. Average values and standard errors for
2^3 independent experiments are shown.
C
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present in the substrate-containing interface at a
mole fraction of approx. 0.002, i.e. one inhibitor
per 500 interface amphiphiles. Thus, it is clear that
this compound inhibits cPLA2K by a speci¢c mech-
anism involving protein^inhibitor interaction [20,21].
In contrast, under similar assay conditions pyrro-
lidine-1 is 17-fold less potent on puri¢ed cPLA2Q
(IC50 = 1.2 WM) than on cPLA2K (Fig. 2C). Unlike
cPLA2K, cPLA2Q is constitutively associated with
membranes in cells. Using isolated membranes from
Sf9 cells expressing cPLA2Q, in which endogenous
membrane phospholipid is used as substrate by mem-
brane-associated cPLA2Q, pyrrolidine-1 (9 10 WM)
did not inhibit the activity of cPLA2Q (data not
shown). This suggests that under more physiological
conditions, pyrrolidine-1 does not inhibit cPLA2Q.
As shown in Fig. 3, pyrrolidine-1 inhibits calcium-
independent cytosolic phospholipase A2 (iPLA2L)
with an IC50 of 8 WM in an assay with 2.5 WM phos-
phatidylcholine substrate. This is almost certainly
due to a non-speci¢c physical e¡ect of pyrrolidine-1
on the structure of the substrate vesicles since the
mole fraction of inhibitor in the interface is approx.
0.8. Inhibition of an interfacial enzyme under condi-
tions of [I]s [S] cannot be interpreted as speci¢c in-
hibition [20,21]. In the same assay, the well-estab-
lished iPLA2L inhibitor BEL [19] displays an IC50
of 30 nM (mole fraction in the interface of 0.012).
No detectable inhibition of the three secreted
phospholipase A2 human groups IIA, V, and X
were observed when up to 10 WM pyrrolidine-1 was
added to a £uorimetric assay with 30 WM 1-palmito-
yl-2-oleoylphosphatidylglycerol vesicles (not shown).
3.2. Mammalian cell studies with pyrrolidine-1
As a ¢rst step in evaluating pyrrolidine-1 as an
inhibitor of cPLA2K action in mammalian cells, we
carried out studies with CHO cells stably overex-
pressing cPLA2K [36]. Arachidonate release in
cPLA2K-transfected cells minus that released from
non-transfected cells is taken as release that is
cPLA2K-dependent. Thus, the transfected CHO cell
system provides an ideal setting for testing pyrroli-
dine-1 as an inhibitor of cPLA2K in vivo. As shown
in Fig. 4, pyrrolidine-1 is a potent inhibitor of CHO
cell arachidonate release induced by 1 WM and 10
WM A23187 in the presence of 1 WM PMA, display-
ing an IC50 of 0.2^0.5 WM in both cases. Inhibition
approaches 100% with 4^10 WM pyrrolidine-1.
Studies with peritoneal macrophages from mouse
containing a targeted disruption of the cPLA2K gene
have shown that virtually all of the arachidonate
release in response to the agonists zymosan and oka-
daic acid is dependent on cPLA2K [38]. Zymosan
(yeast cell walls) induces a transient calcium increase
and mitogen-activated protein kinase activation,
which together fully activate cPLA2K. In contrast,
okadaic acid induces cPLA2K-mediated arachidonic
acid release by unknown mechanisms since it occurs
Fig. 4. Inhibition of arachidonate release in CHO cells that are
stably transfected with cPLA2K. Release of arachidonate was
triggered by 1 WM (b) or 10 WM (a) concentrations of the
Ca2 ionophore A23187 in the presence of 1 WM PMA. Plotted
is the percentage of total cell-incorporated radiolabeled arachi-
donate released in cPLA2K-transfected cells minus that which
was released from non-transferred parental CHO cells. Other
conditions are given in Section 2. Average values and standard
errors for 2^3 independent experiments are shown.
Fig. 3. Inhibition of iPLA2L by BEL (F) and pyrrolidine-1 (E)
measured with the 1-palmitoyl-2-linoleoylphosphatidylcholine
assay. Other conditions are given in Section 2. Average values
and standard errors for 2^3 independent experiments are
shown.
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without an increase in intracellular calcium but is
dependent on activation of mitogen-activated protein
kinase. As shown in Fig. 5, pyrrolidine-1 blocks vir-
tually all of the arachidonate released in response to
zymosan and okadaic acid, with IC50 values of 0.1
and 0.2 WM, respectively.
We also studied the e¡ect of pyrrolidine-1 on ara-
chidonate release from MDCK cells. In MDCK cells,
cPLA2K-mediated arachidonic acid release occurs
through P2Y2 receptor activation by ATP that re-
quires an IP3-mediated increase in intracellular cal-
cium [43]. The MDCK cell model has recently been
used to study the role of calcium and the C2 domain
in regulating the translocation of cPLA2K to speci¢c
membranes in response to ATP and ionomycin (sub-
mitted for publication). As shown in Fig. 6, pyrroli-
dine-1 inhibited virtually all of the arachidonate re-
leased by these two agonists with an IC50 of 0.8 WM
in both cases.
3.3. Concluding remarks
Pyrrolidine-1 displays potent inhibition of cPLA2K
in the sub-micromolar range when analyzed with a
number of in vitro assays. It inhibits cPLA2Q and
iPLA2L only at very high concentrations and prob-
ably by a non-speci¢c mechanism, and it does not
inhibit secreted PLA2s. Given that this compound is
charge neutral and contains a considerable amount
of hydrophobic substituents, it is not surprising that
it penetrates a number of mammalian cells, as judged
by its ability to block cPLA2K-dependent arachidon-
ate release in the sub- to low-micromolar range. A
large number of studies have been reported which
suggest a role for cPLA2K in arachidonate acid re-
lease for eicosanoid biosynthesis and other cell pro-
cesses, for example ion channel modulation [44] and
augmentation of capacitative calcium in£ux [45]. Pyr-
rolidine-1 should be an extremely useful tool to study
cPLA2K functions, especially when studies with
cPLA2K-de¢cient mice are not practical.
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